scispace - formally typeset
Search or ask a question
Institution

Hospital Universitario La Paz

HealthcareMadrid, Spain
About: Hospital Universitario La Paz is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Medicine. The organization has 8960 authors who have published 11499 publications receiving 191509 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: 1H HR‐MAS spectra provide in addition the genetic background for the alterations of choline metabolism observed in high and low grade gliomas, a result that could not be obtained using the tCho/Cr ratio commonly used by in vivo 1H NMR spectroscopy.
Abstract: We investigate the profile of choline metabolites and the expression of the genes of the Kennedy pathway in biopsies of human gliomas (n = 23) using (1)H High Resolution Magic Angle Spinning (HR-MAS, 11.7 Tesla, 277 K, 4000 Hz) and individual genetic assays. (1)H HR-MAS spectra allowed the resolution and relative quantification by the LCModel of the resonances from choline (Cho), phosphocholine (PC) and glycerophosphorylcholine (GPC), the three main components of the combined tCho peak observed in gliomas by in vivo (1)H NMR spectroscopy. All glioma biopsies depicted a prominent tCho peak. However, the relative contributions of Cho, PC, and GPC to tCho were different for low and high grade gliomas. Whereas GPC is the main component in low grade gliomas, the high grade gliomas show a dominant contribution of PC. This circumstance allowed the discrimination of high and low grade gliomas by (1)H HR-MAS, a result that could not be obtained using the tCho/Cr ratio commonly used by in vivo (1)H NMR spectroscopy. The expression of the genes involved in choline metabolism has been investigated in the same biopsies. High grade gliomas depict an upregulation of the beta gene of choline kinase and phospholipase C, as well as a downregulation of the cytidyltransferase B gene, the balance of these being consistent with the accumulation of PC. In the low grade gliomas, phospholipase A(1) and lysophospholipase are upregulated and phospholipase D is downregulated, supporting the accumulation of GPC. The present findings offer a promising procedure that will potentially help to accurately grade glioma tumors using (1)H HR-MAS, providing in addition the genetic background for the alterations of choline metabolism observed in high and low grade gliomas.

81 citations

Journal ArticleDOI
TL;DR: The impact of COVID-19 on the tratamiento del infarto agudo de miocardio con elevacion del segmento ST (IAMCEST) no esta claro as discussed by the authors.
Abstract: Resumen Introduccion y objetivos El impacto del brote de COVID-19 en el tratamiento del infarto agudo de miocardio con elevacion del segmento ST (IAMCEST) no esta claro. El objetivo de este estudio es evaluar los cambios en el tratamiento del IAMCEST durante el brote de COVID-19. Metodos Se utilizo un registro multicentrico, nacional, retrospectivo y observacional de pacientes consecutivos atendidos en 75 centros, se compararon las caracteristicas de los pacientes y de los procedimientos y los resultados hospitalarios en 2 cohortes segun se los hubiera tratado antes o durante la COVID-19. Resultados Los casos con sospecha de IAMCEST disminuyeron el 27,6% y los pacientes con IAMCEST confirmado se redujeron de 1.305 a 1.009 (22,7%). No hubo diferencias en la estrategia de reperfusion (mas del 94% tratados con angioplastia primaria). El tiempo de isquemia fue mas largo durante la COVID-19 (233 [150-375] frente a 200 [140-332] min; p Conclusiones El brote de COVID-19 ha implicado una disminucion en el numero de pacientes con IAMCEST, un aumento del tiempo entre el inicio de los sintomas y la reperfusion y un aumento en la mortalidad hospitalaria. No se han detectado cambios en la estrategia de reperfusion. La combinacion de infeccion por SARS-CoV-2 e IAMCEST fue relativamente infrecuente.

81 citations

Journal ArticleDOI
TL;DR: Immunoenhanced enteral nutrition formulas improved the infection rate in the postoperative of head and neck cancer patients and in the fistula rates, it is observed that technical problems and nutritional status might have played an equally important role, and therefore the positive effect of immunonutrition in this parameter might have been overestimated.
Abstract: Introduction: Significant malnutrition exists in a high percentage of patients with head and neck cancer. Malnutrition is associated with defects in immune function that may impair the host response to malignancy. Malnutrition and immunosupression make patients highly susceptible to postoperative infections and complications. Objectives: Compare two immunoenhanced enteral nutritions with a control diet, and evaluate the effect in postoperative infections, length of stay and inflammatory markers. Patients: A population of 44 patients with oral and laryngeal cancer was enrolled in a randomized trial. At surgery, patients were randomly allocated to three groups: (group I); patients receiving an arginine-enhanced formula (group II); patients receiving a standard polymeric formula, and (group III) patients receiving an arginine, RNA and omega-3 fatty acids enhanced formula, in an isonitrogenous way. Results: The duration of enteral nutrition in the three groups was similar with an average duration of 14,5 ± 8 days. The length of postoperative stay was similar, with an average of 19,8 ± 8,5 days. Wound infections and general infections were more frequent in the control group. Fistula rates were not improved in the enhanced diet groups. No significant intergroup differences in the trend of the two plasma proteins (albumin, transferrin), lymphocytes, weight, IL-6, CPR and TNF  were detected. The control group showed the highest levels of TNF  at the fourteenth postoperative day. Gastrointestinal tolerance and diarrhoea rate were similar in all the patients.

81 citations

Journal ArticleDOI
Isabelle Cleynen1, Worrawat Engchuan2, Matthew S. Hestand3, Matthew S. Hestand1, Matthew S. Hestand4, Tracy Heung5, Tracy Heung6, Aaron M. Holleman7, H. Richard Johnston7, Thomas Monfeuga8, Donna M. McDonald-McGinn9, Donna M. McDonald-McGinn10, Raquel E. Gur9, Bernice E. Morrow11, Ann Swillen1, Jacob A. S. Vorstman12, Jacob A. S. Vorstman10, Jacob A. S. Vorstman13, Carrie E. Bearden14, Eva W.C. Chow6, Eva W.C. Chow12, Marianne Bernadette van den Bree8, Beverly S. Emanuel10, Joris Vermeesch1, Stephen T. Warren7, Michael John Owen8, Pankaj Chopra7, David J. Cutler7, Richard Duncan7, Alex V. Kotlar7, Jennifer G. Mulle7, Anna J. Voss7, Michael E. Zwick7, Alexander Diacou11, Aaron Golden11, Tingwei Guo11, Jhih Rong Lin11, Tao Wang11, Zhengdong Zhang11, Yingjie Zhao11, Christian R. Marshall12, Daniele Merico2, Andrea Jin10, Brenna Lilley10, Harold I. Salmons10, Oanh Tran10, Peter Holmans8, Antonio F. Pardiñas8, James T.R. Walters8, Wolfram Demaerel1, Erik Boot5, Nancy J. Butcher6, Gregory A. Costain6, Gregory A. Costain15, Chelsea Lowther6, Rens Evers16, Therese van Amelsvoort16, Esther D.A. van Duin16, Claudia Vingerhoets16, Jeroen Breckpot1, Koen Devriendt1, Elfi Vergaelen1, Annick Vogels1, T. Blaine Crowley10, Daniel E. McGinn10, Edward Moss10, Robert J. Sharkus10, Marta Unolt10, Elaine H. Zackai9, Elaine H. Zackai10, Monica E. Calkins9, Robert Sean Gallagher9, Ruben C. Gur9, Sunny X. Tang9, Rosemarie Fritsch17, Claudia Ornstein17, Gabriela M. Repetto18, Elemi J. Breetvelt12, Sasja N. Duijff13, Ania Fiksinski13, Ania Fiksinski6, Hayley Moss8, Maria Niarchou8, Kieran C. Murphy19, Sarah E. Prasad19, Eileen Daly20, Maria Gudbrandsen20, Clodagh M. Murphy20, Declan G. Murphy20, Antonio Buzzanca21, Fabio Di Fabio21, Maria Cristina Digilio, Maria Pontillo22, Bruno Marino21, Stefano Vicari22, Karlene Coleman7, Joseph F. Cubells7, Opal Y. Ousley7, Miri Carmel23, Doron Gothelf24, Doron Gothelf23, Ehud Mekori-Domachevsky23, Ehud Mekori-Domachevsky24, Elena Michaelovsky23, Ronnie Weinberger24, Abraham Weizman23, Leila Kushan14, Maria Jalbrzikowski25, Marco Armando26, Stephan Eliez26, Corrado Sandini26, Maude Schneider26, Frédérique Béna27, Kevin M. Antshel28, Wanda Fremont29, Wendy R. Kates29, Raoul Belzeaux, Tiffany Busa, Nicole Philip30, Linda E. Campbell31, Kathryn McCabe32, Kathryn McCabe31, Stephen R. Hooper33, Kelly Schoch34, Vandana Shashi34, Tony J. Simon32, Flora Tassone32, Celso Arango35, David Fraguas35, Sixto García-Miñaur36, Jaume Morey-Canyelles, Jordi Rosell, Damià H. Suñer, Jasna Raventos-Simic, Michael P. Epstein7, Nigel Williams8, Anne S. Bassett12, Anne S. Bassett6, Anne S. Bassett5 
TL;DR: Findings suggest that in addition to the deletion conferring a greatly increased risk to schizophrenia, the risk is higher when the 22q11.2 deletion and common polygenic risk factors that contribute to schizophrenia in the general population are both present.
Abstract: Schizophrenia occurs in about one in four individuals with 22q11.2 deletion syndrome (22q11.2DS). The aim of this International Brain and Behavior 22q11.2DS Consortium (IBBC) study was to identify genetic factors that contribute to schizophrenia, in addition to the ~20-fold increased risk conveyed by the 22q11.2 deletion. Using whole-genome sequencing data from 519 unrelated individuals with 22q11.2DS, we conducted genome-wide comparisons of common and rare variants between those with schizophrenia and those with no psychotic disorder at age ≥25 years. Available microarray data enabled direct comparison of polygenic risk for schizophrenia between 22q11.2DS and independent population samples with no 22q11.2 deletion, with and without schizophrenia (total n = 35,182). Polygenic risk for schizophrenia within 22q11.2DS was significantly greater for those with schizophrenia (padj = 6.73 × 10−6). Novel reciprocal case–control comparisons between the 22q11.2DS and population-based cohorts showed that polygenic risk score was significantly greater in individuals with psychotic illness, regardless of the presence of the 22q11.2 deletion. Within the 22q11.2DS cohort, results of gene-set analyses showed some support for rare variants affecting synaptic genes. No common or rare variants within the 22q11.2 deletion region were significantly associated with schizophrenia. These findings suggest that in addition to the deletion conferring a greatly increased risk to schizophrenia, the risk is higher when the 22q11.2 deletion and common polygenic risk factors that contribute to schizophrenia in the general population are both present.

81 citations

Journal ArticleDOI
TL;DR: Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory, usually mild and transient, and in older patients and in those with less years of education.
Abstract: Chemotherapy can induce cognitive impairment in cancer patients. The main goal of this longitudinal study was to determine the incidence, characteristics, and duration of cognitive dysfunction in patients treated with adjuvant chemotherapy for colon cancer. We assessed cognitive function, quality of life, anxiety and depression, fatigue, and hemoglobin levels in colon cancer patients at three assessment points: pre-chemotherapy (n = 81), post-chemotherapy (n = 73), and after 6-month follow-up (n = 54). All patients were treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) for 6 months. Thirty patients (37 %) had cognitive impairment in the pre-chemotherapy evaluation, mainly in processing speed and psychomotor executive function (Trail Making Test A and B). At the end of treatment, the main domain affected was the verbal memory, with an acute decline detected in 56 % of patients. Fifty-four percent of the patients improved their dysfunction after 6 months of follow-up, whereas 18 (33 %) of them showed worsening in at least one test. Cognitive impairment was most common in older patients and in those with less years of education. Quality of life, anxiety, depression, fatigue, and hemoglobin did not influence the results of the cognitive tests. Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory. This deterioration is usually mild and transient.

81 citations


Authors

Showing all 9020 results

NameH-indexPapersCitations
Jaakko Tuomilehto1151285210682
Vincent Soriano8776234084
Lina Badimon8668235774
Francisco J. Blanco8478933319
Michael A. Gatzoulis8247832562
Jose Lopez-Sendon8146041809
Victor Moreno8063531511
Joaquín Dopazo7539624790
Fernando Rodríguez-Artalejo7451223296
José R. Banegas7442128249
Michael Becker7231718189
Gianfranco Ferraccioli7040226515
Maria-Victoria Mateos6648024278
Manuel Romero-Gómez6442019006
Eulogio García6327015354
Network Information
Related Institutions (5)
Carlos III Health Institute
30K papers, 849K citations

84% related

University of Navarra
26.6K papers, 747.2K citations

83% related

Autonomous University of Barcelona
80.5K papers, 2.3M citations

80% related

University of Barcelona
108.5K papers, 3.7M citations

80% related

University Medical Center Groningen
30.3K papers, 967K citations

80% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202322
202272
20211,335
20201,186
2019889
2018670